NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Change in Working Capital · Q2 FY2026 · quarter ended Jun 2026

Change in working capital turns positive

Q2 FY2026 change in working capital was $1.44M, compared with -$23.84M a year earlier. Trailing-twelve-month change in working capital was -$247K.

Context

  • Change in working capital amounted to 35.3% of revenue in FY2025, down 36.4 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly change in working capital holds near $1.44M or moves back toward the trailing-twelve-month quarterly average of -$61.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.44M-64.8% QoQ
Last fiscal yearDec 2025
-$7.94M-75.7% YoY
LTMJun 2026
-$247K-98.8% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106.1%——
1 year-75.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(7.94M) USD
Year-over-year change
+75.7%

Change in Working Capital vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -98.8% is the 4th highest of 9, against a peer median of -107.4%.
  • Change in working capital amounts to 3.5% of revenue for NAMS, versus a peer median of 11.3%.
NAMS Competitors
Change in Working Capital for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$84.42M USD+1412.1%+68.8%—
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$72.34M USD-34.8%—5.6%
DNLIDenali Therapeutics Inc.LTM Jun 2026$24.36M USD-157.6%—675.8%
BIOABioAge Labs, Inc.LTM Mar 2026$10.29M USD-223.3%—99.7%
SEPNSepterna, Inc.LTM Sep 2026$6.99M USD-104.2%+353.4%7.3%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$3.5M USD-141.8%——
ATHEAlterity Therapeutics LimitedFY2025A$613.68K AUD-110.7%+11.1%11.3%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$247K USD-98.8%—3.5%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$183K USD+100.7%-12.9%—
Peer median (excluding NAMS) —-107.4%+39.9%11.3%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Depreciation & Amortization5K9K49K113K220K
Deferred Income Tax00000
Stock-Based Compensation1.24M4.12M24.57M33.62M59.43M
Change in Working Capital4.47M10.37M5.87M(32.67M)(7.94M)
Accounts Receivables0(4.18M)4.03M0(13.28M)
Inventory00000
Accounts Payables6.56M4.81M5.07M(12.95M)4.91M
Other Working Capital(2.09M)9.75M(3.23M)(19.73M)427K
Other Non-Cash Items6.55M18.8M5.23M81.98M4.34M
Operating Cash Flow(29.51M)10.67M(141.22M)(158.56M)(147.78M)
Capital Expenditures(24K)(221K)(24K)(672K)(246K)
Acquisitions (Net)00000
Purchases of Investments000(62.18M)(296.73M)
Sales of Investments0000122.06M
Other Investing Activities00000
Investing Cash Flow(24K)(221K)(24K)(62.85M)(174.92M)
Debt Repayment0747K000
Common Stock Issued84.7M396.95M8.91M645.51M29.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(5.79M)014M0
Financing Cash Flow84.7M391.91M8.91M659.51M29.52M
Effect of Forex Changes(4.68M)5.25M5.05M(6.8M)12.76M
Net Change in Cash50.49M407.6M(127.28M)431.29M(280.42M)
Free Cash Flow(29.54M)10.44M(141.24M)(159.24M)(148.03M)

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.